ASCO ’26: Bispecifics vs. ADCs, a ‘RAS’ revolution and a step change in prostate cancer
BioPharma Dive
At the year s biggest cancer meeting, a high-stakes clash between two popular drug classes erupted, and scientists made headway against a once-insurmountable foe.
pharminent
June 2, 2026 (Last updated: June 4, 2026)
BioPharma Dive
At the year s biggest cancer meeting, a high-stakes clash between two popular drug classes erupted, and scientists made headway against a once-insurmountable foe.
